Residency · Residency · Critical Care

Shock: Classification and Initial Resuscitation

Definition and Pathophysiology

Defining Shock

Shock is fundamentally defined as acute circulatory failure resulting in inadequate tissue oxygen utilization and cellular dysoxia. It is critically important to recognize that shock is not defined by hypotension alone. A patient may be in a state of compensated shock with a blood pressure that falls within the conventionally accepted normal range, sustained by intense sympathetic activation and neurohormonal compensation that masks the underlying circulatory inadequacy. Relying solely on blood pressure thresholds to identify shock will inevitably result in delayed recognition and treatment.

The key pathophysiological endpoint common to all forms of shock is mitochondrial dysfunction and cellular energy failure. Regardless of the proximate cause, the final common pathway involves a critical reduction in oxygen delivery to the mitochondria, leading to failure of oxidative phosphorylation and cellular energy crisis. When oxygen delivery (DO2) falls below the critical DO2 threshold, approximately 330 mL/min/m2, oxygen consumption (VO2) transitions from being demand-driven to supply-dependent. At this inflection point, the cells shift to anaerobic metabolism, generating far less adenosine triphosphate (ATP) per molecule of glucose and producing lactate as a metabolic byproduct. The resultant lactate accumulation serves as a readily measurable clinical indicator of this supply-demand imbalance.

Cellular Consequences

The cellular consequences of shock unfold in a predictable and devastating cascade once ATP reserves are depleted. The failure of the sodium-potassium ATPase pump, which requires continuous ATP expenditure to maintain the electrochemical gradient across the cell membrane, leads to sodium and water influx into the cell with resultant cellular edema. Simultaneously, anaerobic glycolysis generates lactate and hydrogen ions, producing a progressive metabolic acidosis that further impairs enzyme function and cellular homeostasis.

Intracellular calcium accumulation, normally tightly regulated by ATP-dependent calcium pumps, activates calcium-dependent phospholipases and proteases that degrade the cell membrane and cytoskeletal structures, initiating irreversible cell injury. At the mitochondrial level, opening of the mitochondrial permeability transition pore allows release of cytochrome c into the cytoplasm, triggering the caspase cascade and programmed cell death through apoptosis.

Beyond individual cell injury, shock produces widespread endothelial dysfunction through shedding of the endothelial glycocalyx, a delicate layer of proteoglycans and glycoproteins that lines the luminal surface of blood vessels and serves as a critical regulator of vascular permeability, leukocyte adhesion, and coagulation. Glycocalyx degradation leads to increased vascular permeability, capillary leak, and tissue edema, further compromising oxygen delivery at the microcirculatory level and establishing a vicious cycle of injury.

Classification of Shock

Distributive Shock (66% of ICU shock)

Distributive shock, accounting for approximately two-thirds of all shock cases encountered in the intensive care unit, is characterized by a fundamental derangement in the regulation of vascular tone, leading to pathological vasodilation, maldistribution of blood flow, and capillary leak. Septic shock is by far the most common subtype, resulting from the host inflammatory response to infection that produces widespread vasodilation through nitric oxide overproduction, capillary leak from endothelial injury, and myocardial depression from circulating inflammatory mediators.

Anaphylactic shock results from massive histamine and tryptase release following exposure to an allergen in a sensitized individual, producing profound vasodilation, bronchospasm, and angioedema. Neurogenic shock occurs following spinal cord injury above the level of T6, resulting in loss of sympathetic vascular tone with unopposed parasympathetic activity, producing the characteristic triad of bradycardia, hypotension, and warm extremities. Adrenal crisis represents another important distributive etiology, in which cortisol deficiency leads to impaired vascular tone and diminished responsiveness to circulating catecholamines. Post-cardiopulmonary bypass vasoplegia, occurring in 5-25% of cardiac surgical patients, has been associated with preoperative use of ACE inhibitors, amiodarone, and calcium channel blockers.

Cardiogenic Shock (16% of ICU shock)

Cardiogenic shock results from primary failure of the heart as a pump, producing inadequate cardiac output to meet systemic metabolic demands despite adequate or elevated filling pressures. Acute myocardial infarction remains the most common cause, with left ventricular failure from large anterior infarctions being the prototypical scenario. Mechanical complications of myocardial infarction, including papillary muscle rupture causing acute mitral regurgitation, ventricular septal defect, and free wall rupture with tamponade, represent surgical emergencies that must be rapidly identified.

Additional causes include acute myocarditis (viral, giant cell, or eosinophilic), stress cardiomyopathy (Takotsubo syndrome), acute valvular dysfunction from endocarditis or chordal rupture, and arrhythmia-induced cardiomyopathy from sustained ventricular tachycardia, rapid atrial fibrillation, or complete heart block. The Society for Cardiovascular Angiography and Interventions (SCAI) has developed a five-stage classification system ranging from Stage A (at risk) through Stage E (extremis), providing a standardized framework for communication, prognostication, and escalation of care.

Hypovolemic Shock (16% of ICU shock)

Hypovolemic shock results from a critical reduction in intravascular volume, reducing venous return and cardiac output. Hemorrhagic causes include trauma, gastrointestinal bleeding, ruptured abdominal aortic aneurysm, and postoperative bleeding. The classic four-class hemorrhage classification system describes a progressive clinical deterioration: Class I involves less than 15% blood volume loss with minimal tachycardia and normal blood pressure; Class II (15-30% loss) produces tachycardia and narrowed pulse pressure with anxiety; Class III (30-40% loss) manifests as frank hypotension with tachycardia exceeding 120 beats per minute and confusion; and Class IV (greater than 40% loss) presents with profound hypotension, obtundation, and imminent cardiac arrest.

Non-hemorrhagic hypovolemic shock results from severe dehydration, massive burn injury, third-space fluid sequestration, and severe pancreatitis, where intravascular volume depletion occurs without external blood loss.

Obstructive Shock (2% of ICU shock)

Obstructive shock, the least common subtype, arises from mechanical impediments to cardiac filling or output. Tension pneumothorax produces obstructive shock through compression of the mediastinal structures and impairment of venous return, manifesting with tracheal deviation, absent breath sounds, and jugular venous distension. Cardiac tamponade presents with Beck's triad of hypotension, jugular venous distension, and muffled heart sounds, along with pulsus paradoxus exceeding 10 mmHg. Massive pulmonary embolism causes acute right ventricular failure with an elevated RV/LV ratio greater than 0.9 on computed tomography. Dynamic hyperinflation with auto-PEEP represents an underappreciated cause of obstructive physiology in mechanically ventilated patients with obstructive lung disease.

<image>A four-quadrant diagram illustrating the four types of shock with their hemodynamic profiles. Each quadrant contains a simplified heart and vascular diagram: (1) Distributive - dilated vessels with normal/hyperdynamic heart, showing low SVR and high CO; (2) Cardiogenic - failing heart with congested lungs, showing high SVR, low CO, high PAOP; (3) Hypovolemic - empty vessels with small heart chambers, showing high SVR, low CO, low PAOP; (4) Obstructive - compressed heart with pericardial fluid or PE, showing high SVR, low CO, variable PAOP. Include a central table with hemodynamic parameters (CO, SVR, CVP, PAOP, SvO2) for each type.</image>

Clinical Recognition and Assessment

Clinical Signs of Hypoperfusion

The clinical recognition of shock relies on careful assessment of end-organ perfusion at the bedside. Skin examination provides immediate and valuable information: mottling, best assessed using the knee-centered mottling score ranging from 0 to 5, reflects microcirculatory dysfunction and peripheral vasoconstriction. A mottling score of 4 or greater has been associated with 90% 14-day mortality in the study by Ait-Oufella and colleagues, making it a powerful bedside prognostic indicator. Prolonged capillary refill time, assessed by applying firm pressure to the index finger for 10 seconds and measuring the time to color return, with a threshold of 3 seconds defining abnormal perfusion, has been validated as both a diagnostic and therapeutic endpoint. Cool extremities indicate peripheral vasoconstriction and inadequate tissue perfusion.

Neurological manifestations range from agitation and restlessness in early compensated shock to obtundation and coma as cerebral perfusion deteriorates. Renal hypoperfusion manifests as oliguria, defined as urine output less than 0.5 mL/kg/hr, which serves as a readily measurable indicator of end-organ dysfunction. Hepatic ischemia produces the characteristic ischemic hepatitis pattern, with AST and ALT elevations exceeding 1000 U/L and a rapid rise-and-fall trajectory that distinguishes it from other causes of transaminase elevation.

Laboratory Assessment

Laboratory assessment of shock relies on biomarkers that reflect the metabolic consequences of tissue hypoperfusion. Serum lactate is the most widely used marker: levels exceeding 2 mmol/L indicate tissue hypoperfusion, while levels above 4 mmol/L are associated with mortality rates exceeding 30%. Base deficit correlates with the severity of hemorrhage in trauma, with values below -6 indicating significant hemorrhage. Central venous oxygen saturation below 70% suggests inadequate oxygen delivery relative to demand, although interpretation in sepsis is complicated by impaired oxygen extraction. The venous-arterial CO2 gap exceeding 6 mmHg suggests inadequate cardiac output even when ScvO2 appears acceptable. Point-of-care testing capabilities, including venous blood gas, ionized calcium, hemoglobin, and viscoelastic coagulation testing (TEG/ROTEM), enable rapid bedside decision-making.

Shock Index and Rapid Assessment Tools

The shock index, calculated as heart rate divided by systolic blood pressure, provides a simple bedside screening tool for hemodynamic compromise. The normal range is 0.5-0.7, and a shock index exceeding 1.0 is associated with increased mortality, particularly in trauma and hemorrhage. The modified shock index (heart rate divided by mean arterial pressure), with a threshold above 1.3, may provide additional discriminative value. The quick SOFA (qSOFA) score, incorporating respiratory rate of 22 or greater, altered mentation, and systolic blood pressure of 100 mmHg or less, was developed as a bedside screening tool for sepsis, though it functions as a screening rather than diagnostic instrument.

Initial Resuscitation Strategy

The First 60 Minutes

The initial approach to the shocked patient demands simultaneous assessment and treatment. The clinician must resist the temptation to establish a definitive diagnosis before initiating resuscitation, as the parallel processes of stabilization and evaluation must proceed together in the critically ill patient. The first priority is establishing reliable vascular access with a minimum of two large-bore peripheral intravenous catheters (18-gauge or larger) or central venous access for vasopressor administration and hemodynamic monitoring. An arterial line should be placed early for continuous blood pressure monitoring and facilitation of frequent arterial blood gas analysis.

When infection is suspected as the etiology of shock, empiric broad-spectrum antibiotics must be administered within one hour of recognition, as every hour of delay in appropriate antibiotic therapy has been associated with an approximately 4% increase in mortality. This time-sensitive imperative underscores the need for a systematic, protocol-driven approach to sepsis recognition and antibiotic administration.

Fluid Resuscitation

Initial fluid resuscitation should begin with a measured bolus of 250-500 mL of crystalloid administered over 15-30 minutes, rather than reflexively adhering to the frequently cited but overly simplistic 30 mL/kg recommendation, which was never intended to be applied uniformly to all patients. Fluid responsiveness should be assessed before each subsequent bolus using the dynamic methods described in the hemodynamic monitoring chapter, including passive leg raise, pulse pressure variation, or VTI assessment, to avoid indiscriminate fluid loading.

The choice of crystalloid solution has been the subject of intensive investigation. The SMART trial of 2018 demonstrated that balanced crystalloids (Lactated Ringer's or Plasmalyte) reduced the composite outcome of death, new renal replacement therapy, or persistent renal dysfunction compared to 0.9% normal saline (odds ratio 0.90). However, the subsequent BaSICS trial of 2021 and PLUS trial of 2022 failed to demonstrate significant differences in 90-day mortality between balanced and unbalanced crystalloids, leaving some uncertainty about the magnitude of benefit. Nonetheless, balanced crystalloids are generally preferred given their more physiological electrolyte composition and avoidance of the hyperchloremic acidosis associated with large-volume normal saline administration.

Albumin, evaluated in the SAFE trial, showed no overall mortality difference compared to saline, though a post-hoc subgroup analysis suggested potential benefit in sepsis. Hydroxyethyl starch solutions should be avoided based on the 6S and CHEST trials, which demonstrated increased rates of acute kidney injury and renal replacement therapy with their use.

Vasopressor Initiation

A paradigm-changing concept in shock resuscitation is the recognition that vasopressor therapy should not be delayed while awaiting completion of fluid resuscitation. Early vasopressor use, initiated concurrent with or even before fluid loading, has been associated with improved outcomes in observational studies and is now endorsed by current guidelines. The safety of peripheral vasopressor administration for short durations (up to 24 hours) via proximal veins at or above the antecubital fossa has been established, removing the requirement for central venous access as a prerequisite for vasopressor initiation.

Norepinephrine is the first-line vasopressor for most shock states, supported by the SOAP II trial, which demonstrated that norepinephrine was associated with fewer arrhythmias than dopamine and lower mortality in the cardiogenic shock subgroup. Initial dosing of 0.05-0.1 mcg/kg/min should be titrated to achieve a mean arterial pressure of 65 mmHg or greater. The SEPSISPAM trial evaluated higher MAP targets of 75-80 mmHg versus 65 mmHg and found no overall benefit, although patients with chronic hypertension in the higher-target group required less renal replacement therapy, suggesting that individualized MAP targets based on premorbid blood pressure may be appropriate.

<image>Clinical resuscitation algorithm flowchart beginning with "Suspected Shock" at the top. First branch: ABC assessment with simultaneous IV access and monitoring. Second tier: rapid clinical assessment categorizing into four shock types based on JVD, lung exam, skin temperature, and echo findings. Third tier: type-specific initial interventions -- fluid bolus for hypovolemic, vasopressors for distributive, inotropes/MCS for cardiogenic, and specific interventions for obstructive (needle decompression, pericardiocentesis, thrombolysis). Bottom tier: reassessment endpoints including MAP >=65, lactate clearance, urine output, and capillary refill time. Include specific drug doses and fluid volumes at each decision point.</image>

Goal-Directed Endpoints

Resuscitation endpoints serve as targets against which the adequacy of resuscitation efforts can be measured. A mean arterial pressure of 65 mmHg or greater is the initial hemodynamic target, though individualization based on patient factors including age, premorbid blood pressure, and the presence of chronic hypertension is essential. Lactate clearance of 20% or greater per two hours, validated in numerous studies, provides a metabolic assessment of resuscitation adequacy. The ANDROMEDA-SHOCK trial demonstrated that capillary refill time-guided resuscitation, targeting a CRT of less than 3 seconds assessed at the index finger with 10 seconds of firm pressure, is non-inferior to lactate-guided resuscitation.

Additional resuscitation endpoints include urine output of 0.5 mL/kg/hr or greater, resolution of skin mottling, central venous oxygen saturation of 70% or greater (though this target has been de-emphasized following the ProCESS, ARISE, and ProMISe trials), and normalization of the venous-arterial CO2 gap to less than 6 mmHg.

Type-Specific Resuscitation Principles

Hemorrhagic Shock

The management of hemorrhagic shock has been revolutionized by the principles of damage control resuscitation, which prioritize permissive hypotension (targeting a systolic blood pressure of 80-90 mmHg until surgical hemorrhage control is achieved, except in patients with traumatic brain injury where normotension is required), balanced transfusion with packed red blood cells, fresh frozen plasma, and platelets in a 1:1:1 ratio as established by the PROPPR trial, and early administration of tranexamic acid.

Tranexamic acid (TXA), an antifibrinolytic agent, demonstrated a mortality reduction in the CRASH-2 trial when administered as 1 g intravenously within 3 hours of injury, with a number needed to treat of 67 for mortality. Critically, TXA administered beyond 3 hours was associated with increased mortality, underscoring the importance of early administration. Calcium replacement targeting an ionized calcium of greater than 1.1 mmol/L is essential during massive transfusion, as the citrate preservative in stored blood products chelates calcium, leading to hypocalcemia that impairs both coagulation and cardiac function. TEG/ROTEM-guided component therapy allows targeted correction of specific coagulation deficits and has been shown to reduce overall transfusion requirements.

Cardiogenic Shock

Cardiogenic shock management demands a fundamentally different approach from distributive or hypovolemic shock. Fluid loading must be minimized, with only small aliquots of 250 mL administered with careful reassessment, as these patients are typically volume-overloaded rather than volume-depleted. Inotropic support with dobutamine or milrinone addresses the primary pathology of contractile failure, while norepinephrine provides vasopressor support if concomitant hypotension is present. Early coronary angiography within 2 hours is indicated for acute coronary syndrome-related cardiogenic shock. The IABP-SHOCK II trial demonstrated no mortality benefit of intra-aortic balloon pump counterpulsation in AMI-related cardiogenic shock, and early escalation to mechanical circulatory support with Impella or VA-ECMO should be considered in refractory cases.

Anaphylactic Shock

Epinephrine is the definitive treatment for anaphylaxis and must be administered without delay. The intramuscular route, with a dose of 0.3-0.5 mg of 1:1000 concentration injected into the anterolateral thigh, is preferred for initial management, with doses repeated every 5-15 minutes as needed. An intravenous epinephrine infusion at 0.1-0.5 mcg/kg/min is required for refractory cases. Massive capillary leak in anaphylaxis may require aggressive volume resuscitation with up to 5-7 liters of crystalloid. Adjunctive therapies include diphenhydramine 50 mg IV, ranitidine 50 mg IV, and methylprednisolone 125 mg IV. Glucagon at 1-5 mg IV is specifically indicated for patients on beta-blocker therapy who exhibit refractory anaphylaxis, as it provides positive chronotropic and inotropic effects independent of the beta-adrenergic receptor.

Obstructive Shock

Obstructive shock requires immediate identification and correction of the underlying mechanical cause. Tension pneumothorax demands immediate needle decompression at the second intercostal space in the midclavicular line or the fifth intercostal space at the mid-axillary line, followed by chest tube placement. Cardiac tamponade requires pericardiocentesis, preferably echo-guided, with volume loading serving as a temporizing measure by maintaining filling pressures above the intrapericardial pressure. Massive pulmonary embolism with hemodynamic instability warrants systemic thrombolysis with alteplase 100 mg administered over 2 hours, with surgical embolectomy and catheter-directed therapy as alternatives when thrombolysis is contraindicated or fails.

Monitoring Adequacy of Resuscitation

Avoiding Fluid Overload

The recognition that cumulative positive fluid balance is independently associated with increased mortality in critical illness has fundamentally reshaped the approach to fluid management. The FACTT trial in ARDS demonstrated that a conservative fluid strategy improved ventilator-free days (14.6 versus 11.2) compared to a liberal strategy. More recently, the CLOVERS trial of 2023 compared a restrictive (vasopressor-first) strategy with a liberal (fluid-first) strategy in early sepsis and found no difference in 90-day mortality, supporting the safety of a more restrained approach to initial fluid resuscitation.

The ROSE conceptual framework provides a useful organizing principle for the phases of fluid management in critical illness: Resuscitation (initial aggressive volume loading in the first hours), Optimization (targeted fluid therapy based on responsiveness assessment), Stabilization (maintenance of neutral fluid balance), and Evacuation (active de-resuscitation with diuretic therapy or ultrafiltration to achieve a net negative balance once hemodynamic stability is achieved). This framework emphasizes that fluid management is not a single decision but an evolving strategy that must be adapted to the patient's changing hemodynamic trajectory over time.

<image>Timeline illustration showing the phases of fluid resuscitation in shock using the ROSE framework. Horizontal axis represents time from ICU admission (hours to days). Vertical axis shows cumulative fluid balance. Four distinct phases marked: (1) Resuscitation phase (0-6 hrs) with rapid fluid boluses and rising balance; (2) Optimization phase (6-24 hrs) with targeted fluid based on responsiveness; (3) Stabilization phase (days 1-3) with neutral balance; (4) Evacuation phase (days 3+) with active de-resuscitation and negative balance. Overlay clinical parameters at each phase: lactate, urine output, vasopressor dose. Include danger zone annotation showing risks of both under-resuscitation and over-resuscitation.</image>

Key Clinical Pearls

• Shock is a clinical diagnosis of tissue hypoperfusion -- do not wait for hypotension to intervene
• Always consider mixed shock physiology: 30% of septic shock patients have concomitant myocardial depression
• Early bedside echocardiography is the single most valuable diagnostic tool in undifferentiated shock
• Fluid responsiveness does not equal fluid need -- always consider the risk-benefit of additional fluid
• Norepinephrine is the first-line vasopressor for nearly all shock states; do not delay initiation for fluid loading
• Capillary refill time is a simple, reproducible clinical endpoint that outperformed lactate in ANDROMEDA-SHOCK
• Serial reassessment is mandatory -- the hemodynamic profile of shock evolves over hours to days
• Recognize when to escalate: persistent lactate >4, increasing vasopressor requirement, worsening organ dysfunction despite initial resuscitation

References

1. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-1734.
2. Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378(9):829-839.
3. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
4. Hernandez G, Ospina-Tascon GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654-664.
5. Self WH, Semler MW, Bellomo R, et al. Liberal versus restrictive intravenous fluid therapy for early septic shock: rationale for a randomized trial. Ann Emerg Med. 2018;72(4):457-466.

Read this lecture as Markdown